Chennai Meenakshi Multispeciality Hospital Ltd vs Kmc Speciality Hospitals India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Chennai Meenakshi Multispeciality Hospital Ltd is ₹ 36.4 as of 23 Oct 15:30 . The P/E Ratio of Chennai Meenakshi Multispeciality Hospital Ltd changed from 4.3 on March 2022 to 0 on March 2026 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of KMC Speciality Hospitals (India) Ltd changed from 28 on March 2021 to 27.4 on March 2026 . This represents a CAGR of -0.36% over 6 years The Market Cap of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 7.28 crore on March 2021 to ₹ 24.66 crore on March 2026 . This represents a CAGR of 22.55% over 6 yearsThe Market Cap of KMC Speciality Hospitals (India) Ltd changed from ₹ 355.56 crore on March 2021 to ₹ 1284 crore on March 2026 . This represents a CAGR of 23.87% over 6 years The revenue of Chennai Meenakshi Multispeciality Hospital Ltd for the Jun '26 is ₹ 8.7 crore as compare to the Mar '26 revenue of ₹ 10.05 crore. This represent the decline of -13.43% The revenue of KMC Speciality Hospitals (India) Ltd for the Jun '26 is ₹ 93.58 crore as compare to the Mar '26 revenue of ₹ 84.16 crore. This represent the growth of 11.19% The ebitda of Chennai Meenakshi Multispeciality Hospital Ltd for the Jun '26 is ₹ 0.46 crore as compare to the Mar '26 ebitda of ₹ 0.48 crore. This represent the decline of -4.17% The ebitda of KMC Speciality Hospitals (India) Ltd for the Jun '26 is ₹ 30.29 crore as compare to the Mar '26 ebitda of ₹ 27.78 crore. This represent the growth of 9.04% The net profit of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ -0.38 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of KMC Speciality Hospitals (India) Ltd changed from ₹ 5.51 crore to ₹ 16.57 crore over 9 quarters. This represents a CAGR of 63.12% The Dividend Payout of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of KMC Speciality Hospitals (India) Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Chennai Meenakshi Multispeciality Hospital Ltd

Chennai Meenakshi Multispeciality Hospital Limited, formerly known as Devaki Hospital Limited, was incorporated in 1990.
The Company name was changed from Devaki Hospital Limited to Chennai Meenakshi Multispeciality Hospital Limited in October, 2007.
It is a 100-bedded hospital located in the heart of Chennai at Mylapore.
The hospital has an infrastructure comprising of around 105 Beds including ICU Beds, Operating Theatre, a modern dialysis Unit besides a host of other facilities.
The Company has a pool of talented and experienced doctors who are further supported by a team of highly qualified and experienced and dedicated support staff and cutting edge technology. The Company operate into various departments like Cardiology Department; Casualty Department; Diagnostic Services; Intensive Care Unit; Nephrology Department and Physiotherapy Department.

About KMC Speciality Hospitals (India) Ltd

KMC Speciality Hospitals (India) Limited was originally incorporated as 'Advanced Medical Care Private Limited' on December 31, 1982 and was converted into a Public Limited Company on July 15, 1988.
The name of the Company was changed to 'Seahorse Hospitals Limited' on March 21, 1995 and to its current name 'KMC Speciality Hospitals (India) Limited' with effect from October 24, 2008. The Company is a part of the KMC Group of Hospitals based at Tiruchirappalli.
The Company is a super speciality hospital based in Trichy, belonging to the Kauvery Hospitals Group.
The Company is primarily engaged in the business of rendering medical and healthcare services.
It provide quality healthcare to patients in key specialty areas such as Neurosurgery, Cardiovascular & thoracic surgery, Orthopedics, Plastic and Reconstructive Surgery, Gynecology, Neonatology and Nephrology (including renal transplants).

FAQs for the comparison of Chennai Meenakshi Multispeciality Hospital Ltd and KMC Speciality Hospitals (India) Ltd

Which company has a larger market capitalization, Chennai Meenakshi Multispeciality Hospital Ltd or KMC Speciality Hospitals (India) Ltd?

Market cap of Chennai Meenakshi Multispeciality Hospital Ltd is 27 Cr while Market cap of KMC Speciality Hospitals (India) Ltd is 2,351 Cr

What are the key factors driving the stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and KMC Speciality Hospitals (India) Ltd?

The stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and KMC Speciality Hospitals (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chennai Meenakshi Multispeciality Hospital Ltd and KMC Speciality Hospitals (India) Ltd?

As of October 25, 2026, the Chennai Meenakshi Multispeciality Hospital Ltd stock price is INR ₹36.4. On the other hand, KMC Speciality Hospitals (India) Ltd stock price is INR ₹144.2.

How do dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and KMC Speciality Hospitals (India) Ltd compare?

To compare the dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and KMC Speciality Hospitals (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.